about
Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateViruses for tumor therapyExposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Oncolytic Poxviruses.Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsMGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.Immune-based Therapy Clinical Trials in Hepatocellular CarcinomaMutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.New drug targets in metastatic melanoma.Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses.Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.Immune biomarkers: how well do they serve prognosis in human cancers?Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.Immunotherapy in hepatocellular carcinoma: Primed to make a difference?Combination cancer immunotherapies tailored to the tumour microenvironment.Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphomaCheckpoint inhibition for colorectal cancer: progress and possibilities.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.The Jeremiah Metzger Lecture Cancer in the Twenty-First Century: An Inside View from an Outsider.Zebrafish Xenograft: An Evolutionary Experiment in Tumour Biology.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.PIKKing a way to regulate inflammation.Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer.Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
P2860
Q26782573-99F8441B-1DFA-4704-A83D-191A4DBBA170Q26823826-A5E6ED58-26D2-4541-BFE9-483706BB03F9Q33570005-31C33003-7D85-413A-9F01-35588EF4772AQ34515007-128DDD8D-2820-4516-AEDE-15FA27B717CAQ34661815-D4103DBA-3F67-4030-A410-68984829A5D3Q35234349-2E02C228-D4BE-4F3E-934F-75E0605CEB8BQ35534823-FE79DE62-850A-433F-9EE1-BA40DC20225AQ36413436-05B8B64B-1049-4DF6-9016-91CE06678894Q36571270-C848EF23-E1C1-4223-A43B-74E4A4C0E52CQ37051546-282388E2-5C7F-4482-942E-1B723FCBE0B5Q37066925-6917DE3E-4111-42E8-981D-D4E48C04D1ECQ37534973-9414A3A0-9536-408A-90D8-F106D2BC38D8Q38136595-ABCC8B59-DF58-4F27-B397-F8D3D9A81E8DQ38195656-1E553696-B568-43E7-8333-B23C3FDD62A8Q38206386-E59A6582-AFC6-417B-84CD-866DC373E26DQ38246950-6491453E-EC1D-4515-9EAA-9C92FD822E15Q38262757-0DE8A654-94CC-4819-B004-50DE174CD7D3Q38537768-67381DC8-F453-40CC-94E1-71E7B045A358Q38625948-3F7EF822-27B1-43AA-822A-3CCD89082A3DQ38645178-B5ACC1B1-91DD-4BC3-A6A8-6620665D7154Q38740003-63580A00-2F95-4249-9D1E-5745740CD279Q38838641-88862F71-8BB8-45DD-A5FD-80E46A49A843Q38848219-92E189FB-DBF8-48C1-BA94-683D9000DC9AQ38998443-3CD24220-13D7-4B93-BA87-654A1A02DABDQ41112363-AFA1D71B-8E77-4464-B2BC-EEBB1AA4D7C8Q41673632-3389F6B8-0BDB-4840-8268-157C20009DB0Q46047154-3DF50382-65E0-4149-AF2B-E3E1EF800E2AQ47803583-8444DD8A-A27B-48B2-93BC-DF49D7E1CC2DQ48199574-E03F61C0-C7EA-47E4-B077-EB6AAE3275F2Q50058499-49B048F1-BE32-4E8B-AA43-372BE1BA8624
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Combining cancer immunotherapy and targeted therapy.
@en
type
label
Combining cancer immunotherapy and targeted therapy.
@en
prefLabel
Combining cancer immunotherapy and targeted therapy.
@en
P2860
P1476
Combining cancer immunotherapy and targeted therapy.
@en
P2093
Antoni Ribas
Jedd D Wolchok
P2860
P304
P356
10.1016/J.COI.2013.02.011
P577
2013-04-02T00:00:00Z